Gerard Vockley
Pittsburgh, PANPI 1912973447
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (41.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Biomarin Pharmaceutical Inc. at 26.1% of the total. Reporting peaked in 2024 at $31,696 and has fallen 81.8% since, to $5,767 in 2025.
Across 103 payments — averaging $981.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biomarin Pharmaceutical Inc.$26K
- Amgen$25K
- PTC Therapeutics, Inc.$20K
- Sanofi US Services Inc.$9K
- Agios Pharmaceuticals, Inc.$8K
- Modernatx, Inc.$5K
- plus $8K from 10 others
Across 380 payments — averaging $12,263 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biomarin Pharmaceutical Inc.$1.8M
- Ultragenyx Pharmaceutical Inc.$1.8M
- AstraZeneca$300K
- Acadia Pharmaceuticals Inc$205K
- Shire North American Group Inc$139K
- Sanofi$119K
- plus $352K from 6 others
What the payments were for
- Consulting fees$41,56541%
- Speaking & faculty fees$25,33125%
- Travel & lodging$22,35122%
- Food & beverage$3,0553%
- Education$8,8089%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biomarin Pharmaceutical Inc. | 37 | $26,386 |
| Amgen(2 entities) | 22 | $24,601 |
| PTC Therapeutics, Inc. | 13 | $19,776 |
| Sanofi US Services Inc. | 1 | $9,300 |
| Agios Pharmaceuticals, Inc. | 4 | $8,347 |
| Modernatx, Inc. | 2 | $4,725 |
| AstraZeneca | 11 | $1,535 |
| Acadia Pharmaceuticals Inc | 1 | $1,500 |
| Ipsen Innovation | 1 | $1,500 |
| BTG International Inc. | 2 | $1,500 |
| Tanabe Pharma America, Inc. | 3 | $1,031 |
| Applied Therapeutics, Inc. | 1 | $675 |
| Recordati_rare_diseases_inc. | 1 | $91 |
| Ultragenyx Pharmaceutical Inc. | 2 | $70 |
| Sanofi | 1 | $40 |
| Chiesi USA, Inc. | 1 | $34 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sapropterin Dihydrochloride | 11 | $319,940 |
| BuphenylSodium Phenylbutyrate | 11 | $280,616 |
| DojolviTriheptanoin | 12 | $181,842 |
| Leucovorin Calcium | 12 | $2,875 |
| Sodium Citrate-Citric AcidCitric Acid/Sodium Citrate | 12 | $212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenBuphenyl | $24,601 | $280,61611 claims |
| Ultragenyx Pharmaceutical Inc.Dojolvi | $70 | $181,84212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few providers in Pennsylvaniaon file to place this against a meaningful peer group, so we don't.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.